NuCana's R&D On Agents For Drug-Resistant Cancers Gets IPO Boost
Executive Summary
The UK biotech plans to move its early clinical-stage anticancers, designed to improve the efficacy and tolerability of established agents, through its R&D pipeline with the proceeds of its recent US IPO.
You may also be interested in...
UK's Nightstar NASDAQ Listing Backs British Biotech Build-Up Strategy
The UK developer of gene therapies for inherited eye diseases has listed on NASDAQ, adding to its monetary resources for competing in what is becoming a competitive sector for drug development, and going some way to validating the approach of the UK healthcare investment firm, Syncona, to growing biotech companies.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.